ATE323102T1 - Pyroglutaminsäurederivate und damit verwandte verbindungen, die die durch vla-4 vermittelte leukozytenadhäsion verringern - Google Patents

Pyroglutaminsäurederivate und damit verwandte verbindungen, die die durch vla-4 vermittelte leukozytenadhäsion verringern

Info

Publication number
ATE323102T1
ATE323102T1 AT00904486T AT00904486T ATE323102T1 AT E323102 T1 ATE323102 T1 AT E323102T1 AT 00904486 T AT00904486 T AT 00904486T AT 00904486 T AT00904486 T AT 00904486T AT E323102 T1 ATE323102 T1 AT E323102T1
Authority
AT
Austria
Prior art keywords
acid derivatives
related compounds
leukocyte adhesion
mediated leukocyte
vla
Prior art date
Application number
AT00904486T
Other languages
English (en)
Inventor
Darren B Dressen
Anthony Kreft
Dennis Kubrak
Charles William Mann
Michael A Pleiss
Gary Paul Stack
Eugene D Thorsett
Original Assignee
Elan Pharm Inc
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharm Inc, Wyeth Corp filed Critical Elan Pharm Inc
Application granted granted Critical
Publication of ATE323102T1 publication Critical patent/ATE323102T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06173—Dipeptides with the first amino acid being heterocyclic and Glp-amino acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT00904486T 1999-01-26 2000-01-21 Pyroglutaminsäurederivate und damit verwandte verbindungen, die die durch vla-4 vermittelte leukozytenadhäsion verringern ATE323102T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23866199A 1999-01-26 1999-01-26

Publications (1)

Publication Number Publication Date
ATE323102T1 true ATE323102T1 (de) 2006-04-15

Family

ID=22898814

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00904486T ATE323102T1 (de) 1999-01-26 2000-01-21 Pyroglutaminsäurederivate und damit verwandte verbindungen, die die durch vla-4 vermittelte leukozytenadhäsion verringern

Country Status (12)

Country Link
EP (2) EP1144435B1 (de)
JP (1) JP2002535341A (de)
CN (1) CN1195773C (de)
AR (1) AR022405A1 (de)
AT (1) ATE323102T1 (de)
AU (1) AU2623800A (de)
CA (1) CA2358093A1 (de)
DE (1) DE60027268T2 (de)
ES (1) ES2262504T3 (de)
HK (1) HK1046146B (de)
TW (1) TWI224110B (de)
WO (1) WO2000043413A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1144435B1 (de) * 1999-01-26 2006-04-12 Elan Pharmaceuticals, Inc. Pyroglutaminsäurederivate und damit verwandte verbindungen, die die durch vla-4 vermittelte leukozytenadhäsion verringern
US6407066B1 (en) * 1999-01-26 2002-06-18 Elan Pharmaceuticals, Inc. Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4
JP5401218B2 (ja) * 2009-09-03 2014-01-29 東京応化工業株式会社 レジスト組成物、レジストパターン形成方法
CN108299218A (zh) * 2017-01-12 2018-07-20 南京红杉生物科技有限公司 一种4-溴-d-苯丙氨酸的合成方法
CN109180552B (zh) * 2018-09-26 2021-10-26 沈阳药科大学 取代的5-氧代吡咯烷类衍生物及其制备方法和应用
FI3873884T3 (fi) 2018-10-30 2025-02-24 Gilead Sciences Inc 3-(kinolin-8-yyli)-1,4-dihydropyrido[3,4-d]pyrimidiini-2,4-dionijohdannaisia alfa-4-beta-7-integriinin estäjinä tulehdussairauksien hoidossa
JP7189368B2 (ja) 2018-10-30 2022-12-13 ギリアード サイエンシーズ， インコーポレイテッド アルファ４ベータ７インテグリンの阻害のための化合物
ES3013256T3 (en) 2018-10-30 2025-04-11 Gilead Sciences Inc Imidazo[1,2-a]pyridine derivatives as alpha4beta7 integrin inhibitors for the treatment of inflammatory diseases
EP3873605B1 (de) 2018-10-30 2024-10-23 Gilead Sciences, Inc. Verbindungen zur inhibierung von alpha4-beta7-integrin
WO2021030438A1 (en) 2019-08-14 2021-02-18 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2964295A (en) * 1994-07-11 1996-02-09 Athena Neurosciences, Inc. Inhibitors of leukocyte adhesion
DK0910575T3 (da) * 1996-06-21 2003-02-03 Takeda Chemical Industries Ltd Fremgangsmåde til fremstilling af peptider
IL133639A0 (en) * 1997-07-31 2001-04-30 Elan Pharm Inc Dipeptide and related compounds which inhibit leukocyte adhesion mediated by vla-4
TW591026B (en) * 1998-06-23 2004-06-11 Upjohn Co Inhibitors of alpha4beta1 mediated cell adhesion
EP1144435B1 (de) * 1999-01-26 2006-04-12 Elan Pharmaceuticals, Inc. Pyroglutaminsäurederivate und damit verwandte verbindungen, die die durch vla-4 vermittelte leukozytenadhäsion verringern

Also Published As

Publication number Publication date
CN1195773C (zh) 2005-04-06
AU2623800A (en) 2000-08-07
AR022405A1 (es) 2002-09-04
WO2000043413A2 (en) 2000-07-27
DE60027268D1 (de) 2006-05-24
CA2358093A1 (en) 2000-07-27
JP2002535341A (ja) 2002-10-22
EP1144435B1 (de) 2006-04-12
ES2262504T3 (es) 2006-12-01
DE60027268T2 (de) 2007-03-15
HK1046146B (zh) 2005-07-29
CN1344274A (zh) 2002-04-10
TWI224110B (en) 2004-11-21
WO2000043413A3 (en) 2000-11-30
EP1144435A2 (de) 2001-10-17
EP1612215A1 (de) 2006-01-04
HK1046146A1 (en) 2002-12-27

Similar Documents

Publication Publication Date Title
DE60036918D1 (de) Verbindungen die die vla-4 vermittelte adhäsion von leukozyten inhibieren
EP1558104A4 (de) Mehrbahniges reissverschlusssystem
PL377740A1 (pl) Kompozycje farmaceutyczne ze zmodyfikowaną zaróbką
IL172777A0 (en) Specific glucocoticosteroid compound having anti-inflammatory activity
HUP0004259A3 (en) Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4, pharmaceutical compositions comprising thereof
ZA200601685B (en) Novel compounds having inhibitory activity against sodium-dependant transporter
AU2623900A (en) Compounds which inhibit leukocyte adhesion mediated by vla-4
PL377695A1 (pl) Sinomenina i związki synomeniny, synteza i zastosowanie
WO2002076935A8 (en) Novel a-lipoic acid derivative and use thereof
ATE299490T1 (de) Multizyklische verbindungen zur hemmung der durch vla-4 vermittelten leukozytenadhäsion
ATE323102T1 (de) Pyroglutaminsäurederivate und damit verwandte verbindungen, die die durch vla-4 vermittelte leukozytenadhäsion verringern
AU2003261988A8 (en) Versatile linker compound and ligand, and method for preparation thereof
IN2009CH01478A (en) Asymmetric urea compound and process for producing asymmetric compound by asymmetric conjugate addition reaction with the same as catalyst
AU2003245020A1 (en) Bar clamp
AU2003232859A1 (en) 2,7,12,17 alkenyl, aryl and heteroaryl derived from 3,6,13,16-tetraazaporphycene, method, intermediate compound and corresponding utilizations
EP1431302A4 (de) Verfahren zur synthese metallorganischer verbindungen
GB2418030A8 (en) A process flow tracking system
AU2003239397A1 (en) Seal bar assembly
AU2003276330A8 (en) Novel compounds comprising a thiocarbonyl-sulfanyl group, which can be used for the radical synthesis of alpha-perfluoroalkylamines
AU3348700A (en) Compounds which inhibit leukocyte adhesion mediated by vla-4
GB0230025D0 (en) Novel pharmaceuticals
TWI265151B (en) Method of purifying niobium compound and/or tantalum compound
GB0204392D0 (en) Pharmaceutical compound
TW560581U (en) Fastener for fastening two members
AU2003269732A1 (en) Catalyst for the synthesis of ammonia

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties